MRNA

NEUTRALLOW confidence

Moderna, Inc. | NasdaqGS

Current PriceUSD 198.88

Asset ClassStock

Market CapN/A

AERINVEST Score51/100

Dividend YieldN/A

Live quote available with 45/100 data completeness. 7 data sources did not respond, so parts of this page are incomplete — the gaps are listed below rather than filled with estimates.Not financial advice. Verify sources before allocating capital.

Stock analysisStock-specific model

Is this company profitable, reasonably valued, financially resilient, and supported by catalysts?

Next Best ActionMonitor patience

Constructive when valuation, ROE/FCF, balance sheet, dividend safety, and catalysts point in the same direction.

Premium WorkflowAlerts, exports, and backtests

See plans

About Moderna, Inc.

Moderna, Inc. is classified as a EQUITY. Company-specific fundamentals were not returned by the configured provider.

MoatNot assessed. A moat claim needs return on invested capital held above the cost of capital across a full cycle, plus a barrier expressible in the time or money a competitor would have to spend to cross it. Neither is derived here yet.

CustomersCustomer quality is not inferred from ticker alone.

Operating leverageOperating leverage requires more complete revenue, margin, and cash-flow history.

Stock analysis

Decision questionIs this company profitable, reasonably valued, financially resilient, and supported by catalysts?

Add signal contextConstructive when valuation, ROE/FCF, balance sheet, dividend safety, and catalysts point in the same direction.

Caution signalAvoid when multiple expansion is the only thesis, debt is heavy, FCF is weak, or data quality is too incomplete.

P/EN/A

Valuation sanity check. Lower is not always better, but extreme multiples need stronger growth evidence.

ROEN/A

Profitability and potential moat proxy for operating businesses.

FCF/shareN/A

Positive cash generation matters more than accounting story.

Debt/EquityN/A

Balance-sheet pressure can break even a good growth story.

Dividend yieldN/A

Useful for income investors, but must be paired with payout and cash-flow safety.

AI Consensus

51NEUTRAL

MRNA is rated NEUTRAL with low confidence: the price is within the valuation model's fair-value range (base USD 115.47).

Downside / Cautious / Growth | 12M Targets

Downside Path20%

USD 40.00-80% vs current

Low end of the valuation range (Analyst target consensus).

Cautious Path55%

USD 115.47-42% vs current

Weighted fair value from Analyst target consensus; valuation confidence 40/100.

Growth Path25%

USD 170.00-15% vs current

High end of the valuation range (Analyst target consensus).

Revenue Streams

Revenue by segment is not available for MRNA. Segment detail comes from the company's own annual filing with the SEC; it is missing for non-US filers and for issuers that do not tag it in a form that reconciles to reported revenue.